Close Menu

NEW YORK (GenomeWeb) – Becton Dickinson reported today that its fiscal fourth quarter revenues rose 6 percent year over year, driven by strong growth in its medical segment that was partly offset by flat revenue growth in the diagnostics business.  

For the three months ended Sept. 30, the company posted revenues of $3.23 billion compared to $3.06 billion in the year-ago quarter, beating Wall Street analysts' average estimate of $3.22 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.